Key result
Perfusion of donor kidneys with a lentiviral-based SHARP-2 shRNAi construct prolonged the median survival time of rat kidney transplant recipients by 4 to 5 days compared with control groups.
Why the study?
Does SHARP-2 gene silencing with a lentiviral-based shRNAi construct prolong survival in rat kidney transplant recipients?
Does SHARP-2 gene silencing with a lentiviral-based shRNAi construct prolong survival in rat kidney transplant recipients?
SHARP-2 gene silencing via a lentiviral shRNAi construct reduces IL-2 and IFN-gamma expression and prolongs survival in a rat kidney transplant model.
Answers are grounded in this paper and cite their sources.
SHARP-2 shRNAi perfusion may extend rodent allograft survival; hypothesis-generating and should not yet influence clinical practice.
Split- and hairy-related protein-2 (SHARP-2) controls the expression of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma), which both play a key role in transplant rejection. This study was designed to investigate whether SHARP-2 short hairpin RNA interference (shRNAi) could prolong the survival of rat kidney transplant recipients. A lentiviral-based shRNAi construct, LV-SHARP-2iC, showed a SHARP-2 gene silencing efficiency of 84% in normal rat kidney cells. In activated T-cells, SHARP-2 gene silencing with the LV-SHARP-2iC construct resulted in 61% and 69% down-regulation of IL-2 and IFN-gamma, respectively, compared with a scramble control construct. When donor kidney was perfused with 5 x 10(7) transforming units of the LV-SHARP-2iC construct, the median survival time of the transplant recipients was prolonged by 4 - 5 days compared with control groups. In conclusion, recombinant lentiviral LV-SHARP-2iC construct effectively silenced SHARP-2 gene expression, which reduced IL-2 and IFN-gamma mRNA expression and prolonged rat kidney transplant recipients' survival.
No takes yet. Share an insight, caveat, or question.
Shou et al. (2009) studied Kidney transplant rejection. Lentiviral-based SHARP-2 shRNAi construct (LV-SHARP-2iC) vs. Control groups was evaluated on Median survival time (prolonged by 4-5 days). Perfusion of donor kidneys with a lentiviral-based SHARP-2 shRNAi construct prolonged the median survival time of rat kidney transplant recipients by 4 to 5 days compared with control groups.
Synapse has enriched 10 related papers. Consider them for comparative context: